{
    "clinical_study": {
        "@rank": "6655", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo gel capsule, dosage matches number of Ataciguat capsules for each respective dose, capsules taken once daily with breakfast for 14 consecutive days."
            }, 
            {
                "arm_group_label": "Ataciguat", 
                "arm_group_type": "Active Comparator", 
                "description": "Ataciguat, orally administered gel capsule, 50, 100, or 200 mg, once per day with breakfast for 14 consecutive days"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine whether Ataciguat (HMR1766) is well-tolerated in patients with\n      mild to moderate calcific aortic valve stenosis.  The primary focus of these studies will be\n      on changes in blood pressure and orthostatic tolerance (i.e., ability to stand up without\n      passing out), and determining whether treatment with Ataciguat results in significant\n      reductions in blood pressure in this patient population."
        }, 
        "brief_title": "Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Mild to Moderate Calcific Aortic Valve Stenosis", 
        "condition_browse": {
            "mesh_term": [
                "Aortic Valve Stenosis", 
                "Constriction, Pathologic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 50 years\n\n          -  Male or female sex\n\n          -  Aortic valve area greater than 1.0 cm2 but less than 2.0 cm2\n\n          -  Aortic valve calcium levels greater than 300 arbitrary units from chest CT\n\n          -  Ejection fraction >50%\n\n        Exclusion Criteria:\n\n          -  History of orthostatic intolerance or symptomatic hypotension\n\n          -  Positive pregnancy test during screening visit\n\n          -  Nitrate use or \u03b1-antagonist medication use within 24 hours\n\n          -  Systolic blood pressure <110 mm Hg\n\n          -  Mean systemic arterial pressure <75 mm Hg\n\n          -  Severe mitral or aortic regurgitation\n\n          -  Retinal or optic nerve problems\n\n          -  Recent (\u226430 days) acute coronary syndrome\n\n          -  Oxygen saturation <90% on room air\n\n          -  Congenital valve disease\n\n          -  Hepatic dysfunction/elevated liver enzymes\n\n          -  Prescription of drugs known to alter nitric oxide-soluble guanylate cyclase-cyclic\n             guanosine monophosphate signaling (sildenafil, nitrates, etc.)\n\n          -  History of orthostatic intolerance\n\n          -  Concomitant participation in other trials at Mayo Clinic or elsewhere."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02049203", 
            "org_study_id": "13-005387"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ataciguat", 
                "intervention_name": "Ataciguat", 
                "intervention_type": "Drug", 
                "other_name": "HMR1766"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo gel capsule of identical composition to Active group, but does not have active compound."
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "email": "engrav.pamela@mayo.edu", 
                "last_name": "Pam Engrav", 
                "phone": "507-255-6938"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "investigator": [
                {
                    "last_name": "Jordan D Miller, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Maurice E Sarano, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Hartzell V Schaff, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Michael J Joyner, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase Ib Randomized, Placebo-controlled, Double-blinded Study Evaluating the Safety of Ataciguat (HMR1766) in Patients With Moderate Calcific Aortic Valve Stenosis", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Jordan Miller, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary objective of the current study is to determine whether Ataciguat (HMR1766) is well-tolerated by patients with moderate calcific aortic valve stenosis. In this particular patient population, incidence of orthostatic intolerance/symptomatic hypotension is a potential concern.", 
                "measure": "Number of patients experiencing orthostatic hypotension", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline - 14 days"
            }, 
            {
                "description": "The primary objective of the current study is to determine whether Ataciguat (HMR1766) is well-tolerated by patients with moderate calcific aortic valve stenosis. In this particular patient population, incidence of orthostatic intolerance/symptomatic hypotension is a potential concern.  Transitioning from sitting to standing is a functional test that will allow us to examine the effects of Ataciguat on blood pressure regulation in response to a relevant orthostatic stress.", 
                "measure": "The change in blood pressure following the transition from sitting to standing", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline - 14 days"
            }, 
            {
                "description": "The primary objective of the current study is to determine whether Ataciguat (HMR1766) is well-tolerated by patients with moderate calcific aortic valve stenosis. In this particular patient population, incidence of orthostatic intolerance/symptomatic hypotension is a potential concern. Tilt table testing will allow us to examine the effects of Ataciguat on blood pressure regulation in response to a tightly controlled orthostatic stress.", 
                "measure": "The change in blood pressure following progressive head-up tilt", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline - 14 days"
            }, 
            {
                "description": "The primary objective of the current study is to determine whether Ataciguat (HMR1766) is well-tolerated by patients with moderate calcific aortic valve stenosis. In this particular patient population, incidence of orthostatic intolerance/symptomatic hypotension is a potential concern. Evaluating subject perceptions of light-headedness/orthostatic intolerance will help us to understand the relationship between changes in blood pressure and changes in symptoms in this patient population before and after treatment with Ataciguat.", 
                "measure": "Subject self-reports of light-headedness/orthostatic intolerance during the standing test and the head-up tilt testing", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline - 14 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02049203"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Jordan D. Miller, Ph.D.", 
            "investigator_title": "Assistant Professor of Surgery", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Center for Advancing Translational Science (NCATS)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Sanofi-Synthelabo", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Jordan D. Miller, Ph.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}